华仁药业：盐酸异丙肾上腺素化学原料药上市申请获批准

Core Viewpoint - Huaren Pharmaceutical's subsidiary, Anhui Hengxing Pharmaceutical, has received approval from the National Medical Products Administration for the marketing application of Isoproterenol Hydrochloride, indicating a significant advancement in the company's product portfolio and potential market opportunities [1]. Group 1 - The approved drug, Isoproterenol Hydrochloride, is a non-selective β-adrenergic agonist that strongly stimulates both β1 and β2 receptors, showcasing powerful positive inotropic, positive chronotropic, and bronchodilator effects [1]. - The clinical applications of Isoproterenol Hydrochloride primarily include treatment for cardiogenic or septic shock, complete atrioventricular block, cardiac arrest, and acute bronchial asthma attacks [1].